Welkom bij Scalda & Bohn Stafleu van Loghum
Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.
01-05-2012 | Nascholing
Behandeling gelokaliseerd prostaatcarcinoom
Auteurs: Esther Hamoen, prof.dr. Fred Witjes
Log in om toegang te krijgenshare
DELEN
Deel dit onderdeel of sectie (kopieer de link)
-
Optie A:
-
Optie B:Deel de link per e-mail
Samenvatting
Hamoen EHJ, Witjes JA. Behandeling gelokaliseerd prostaatcarcinoom. Huisarts Wet 2012;55(5):222-4.
Naast de specialist speelt de huisarts een grote rol in het begeleiden van patiënten die behandeld worden voor prostaatcarcinoom. De standaard behandelingsopties bij gelokaliseerd prostaatcarcinoom zijn, naast actief volgen, radicale prostatectomie en radiotherapie. Dit zijn ingrijpende behandelingen met lastige bijwerkingen. Nu de incidentie van prostaatkanker toeneemt, stijgt ook de vraag naar minder invasieve behandelingsmethoden met hopelijk minder bijwerkingen. Dit nascholingsartikel gaat in op de uitkomsten en bijwerkingen van de standaardbehandelingen, en op twee relatief nieuwe ontikkelingen: cryochirurgie enhigh intensity focused ultrasound(HIFU). Deze zogeheten focale therapieën zijn sterk in opkomst. Juist omdat ze nieuw zijn en volop in ontwikkeling, is over hun effectiviteit en bijwerkingen nog weinig met zekerheid te zeggen. Zowel cryochirurgie als HIFU hebben redelijk wat bijwerkingen – met name urineretentie en erectiele disfunctie – en de resultaten op lange termijn zijn onzeker. Daarom zijn ze voorlopig nog geen serieus alternatief voor de standaardbehandelingen.
Log in om toegang te krijgen
Literatuur
1.
go back to reference Cijfers over kanker [internet]. Utrecht: Vereniging Integrale Kankercentra, 2011 [update 2012].www.cijfersoverkanker.nl.
Cijfers over kanker [internet]. Utrecht: Vereniging Integrale Kankercentra, 2011 [update 2012].www.cijfersoverkanker.nl.
2.
go back to reference Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.PubMedCrossRef
Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-101.PubMedCrossRef
3.
go back to reference Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.PubMedCrossRef
Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.PubMedCrossRef
4.
go back to reference Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002;95:2126-35.PubMedCrossRef
Vicini FA, Martinez A, Hanks G, Hanlon A, Miles B, Kernan K, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002;95:2126-35.PubMedCrossRef
5.
go back to reference Fahmy WE, Bissada NK. Cryosurgery for prostate cancer. Arch Androl 2003;49:397-407.PubMedCrossRef
Fahmy WE, Bissada NK. Cryosurgery for prostate cancer. Arch Androl 2003;49:397-407.PubMedCrossRef
6.
go back to reference Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int 2004;93:710-4.PubMedCrossRef
Rees J, Patel B, MacDonagh R, Persad R. Cryosurgery for prostate cancer. BJU Int 2004;93:710-4.PubMedCrossRef
7.
go back to reference Han KR, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004;93:14-8.PubMedCrossRef
Han KR, Belldegrun AS. Third-generation cryosurgery for primary and recurrent prostate cancer. BJU Int 2004;93:14-8.PubMedCrossRef
8.
go back to reference Beerlage HP, Thuroff S, Madersbacher S, Zlotta AR, Aus G, De Reijke TM, et al. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37:2-13.PubMedCrossRef
Beerlage HP, Thuroff S, Madersbacher S, Zlotta AR, Aus G, De Reijke TM, et al. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37:2-13.PubMedCrossRef
9.
go back to reference Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.PubMedCrossRef
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.PubMedCrossRef
10.
go back to reference Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int 2011;107:1362-8.PubMedCrossRef
Nguyen CT, Jones JS. Focal therapy in the management of localized prostate cancer. BJU Int 2011;107:1362-8.PubMedCrossRef
11.
go back to reference Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57:518-23.PubMedCrossRef
Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57:518-23.PubMedCrossRef
12.
go back to reference Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.PubMedCrossRef
Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002;167:528-34.PubMedCrossRef
13.
go back to reference Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external radiotherapy > or = 72 Gy, permanent seed implantation or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.CrossRef
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy < 72 Gy, external radiotherapy > or = 72 Gy, permanent seed implantation or combined seeds/external beam radiotherapy for stage T1-2 prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:25-33.CrossRef
14.
go back to reference Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60:3-11PubMedCrossRef
Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002;60:3-11PubMedCrossRef
15.
go back to reference Donelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 2002;60:645-9.CrossRef
Donelly BJ, Saliken JC, Ernst DS, Ali-Ridha N, Brasher PM, Robinson JW, et al. Prospective trial of cryosurgical ablation of the prostate: Five year results. Urology 2002;60:645-9.CrossRef
16.
go back to reference Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 2003;170:1126-30.PubMedCrossRef
Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: Preliminary multicenter experience. J Urol 2003;170:1126-30.PubMedCrossRef
17.
go back to reference Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: The University of California, San Francisco experience. J Urol 1999;162:427-32.PubMedCrossRef
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: The University of California, San Francisco experience. J Urol 1999;162:427-32.PubMedCrossRef
18.
go back to reference De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: Complication rates and biochemical recurrence. BJU Int 2000;85:281-6.CrossRef
De La Taille A, Benson MC, Bagiella E, Burchardt M, Shabsigh A, Olsson CA, et al. Cryoablation for clinically localized prostate cancer using an argon-based system: Complication rates and biochemical recurrence. BJU Int 2000;85:281-6.CrossRef
19.
go back to reference Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60:12-8.PubMedCrossRef
Robinson JW, Donnelly BJ, Saliken JC, Weber BA, Ernst S, Rewcastle JC. Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery. Urology 2002;60:12-8.PubMedCrossRef
20.
go back to reference Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: Quality of life outcomes. Cancer 2009;115:4695-704.PubMedCrossRef
Robinson JW, Donnelly BJ, Siever JE, Saliken JC, Ernst SD, Rewcastle JC, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: Quality of life outcomes. Cancer 2009;115:4695-704.PubMedCrossRef
21.
go back to reference Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7.PubMedCrossRef
Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007;51:381-7.PubMedCrossRef
22.
go back to reference Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience. Int J Urol 2009;16:881-6.PubMedCrossRef
Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, et al. Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: Eight-year experience. Int J Urol 2009;16:881-6.PubMedCrossRef
23.
go back to reference Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17:667-72.CrossRef
Madersbacher S, Marberger M. High-energy shockwaves and extracorporeal high-intensity focused ultrasound. J Endourol 2003;17:667-72.CrossRef
24.
go back to reference Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999;161:156-62.PubMedCrossRef
Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999;161:156-62.PubMedCrossRef
Metagegevens
- Titel
- Behandeling gelokaliseerd prostaatcarcinoom
- Auteurs
-
Esther Hamoen
prof.dr. Fred Witjes
- Publicatiedatum
- 01-05-2012
- Uitgeverij
- Bohn Stafleu van Loghum
- DOI
- https://doi.org/10.1007/s12445-012-0103-x